Q-omics provides the consensus-scored ZNF672 profile across patient tissues and cancer cell-line models. ZNF672 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF672 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, ZNF672 RNA expression shows 19,252 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where ZNF672 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF672 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF672 survival associations across molecular data types. ZNF672 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF672 RNA expression–survival associations across cancer types. High ZNF672 expression shows unfavorable associations in ACC, UVM, KICH and LAML, but favorable associations in HNSC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF672 RNA expression.
This table summarizes ZNF672 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF672. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF672 shows lower tumor expression in THCA and higher tumor expression in LIHC, UCEC, BRCA, STAD and CHOL. The LIHC box plot shows higher ZNF672 RNA expression in tumor versus normal tissue (log2 FC = +1.222, t-test p < 0.001).
This table shows molecular features associated with ZNF672 in patient tissues and cancer cell lines. In patient samples, ZNF672 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF672 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
